What Happened
- India's first dedicated registry of childhood cancer survivors — the Indian Childhood Cancer Survivorship (C2S) study — has been published in The Lancet Regional Health Southeast Asia, revealing a 94.5% five-year overall survival rate among the study cohort.
- The registry, initiated in 2016 by researchers from AIIMS New Delhi and Rajiv Gandhi Cancer Institute and Research Centre, examined 5,419 children diagnosed with cancer before age 18 and in remission after treatment, drawn from 20 centres across the country.
- Acute leukaemia was the most common diagnosis (40.9% of cases), followed by other cancers.
- Treatment modalities: chemotherapy for 94.7% of participants, surgery for 30%, and radiotherapy for 26.3%.
- For the 2,266 survivors followed up for at least two years post-treatment, the five-year overall survival rate rose to 98.2%, with event-free survival at 95.7%.
- The study is among the world's first childhood cancer survivor registries from a resource-limited setting, providing a data baseline previously absent in India and contributing to the global evidence base on survivorship in low- and middle-income countries (LMICs).
Static Topic Bridges
Childhood Cancer Epidemiology in India: Scale and Profile
Childhood cancer (cancers in individuals below 18 years of age) is biologically and clinically distinct from adult cancer. India faces a dual burden: a high absolute number of childhood cancer cases (given its population size) and relatively lower survival rates compared to high-income countries, historically attributable to late diagnosis, limited access to treatment, and resource constraints.
- India accounts for approximately 10% of global childhood cancer cases.
- Estimated new childhood cancer cases annually in India: 50,000–75,000 (exact figures underestimated due to poor reporting infrastructure).
- Most common childhood cancers in India: acute lymphoblastic leukaemia (ALL), brain tumours, retinoblastoma, Wilms' tumour, and bone sarcomas.
- In high-income countries (USA, UK), childhood cancer overall survival rates approach 85–90%.
- Historically, survival rates for childhood ALL in India were approximately 65% on equivalent treatment protocols — significantly below the 85–90% in high-income countries, largely due to treatment abandonment, infection-related mortality, and limited access to supportive care.
- The C2S study's 94.5% overall survival, drawn from 20 centres (primarily tertiary care institutions), likely reflects outcomes at leading institutions rather than the national average.
Connection to this news: The C2S study provides India's first structured national-level data on childhood cancer outcomes. Prior to this, India lacked a survivor registry, making it impossible to assess late effects of treatment (secondary cancers, organ damage, cognitive effects) or design targeted survivor follow-up programmes.
Leukaemia: Biology, Treatment Protocols, and the ICiCLe Model
Acute Lymphoblastic Leukaemia (ALL) — the dominant diagnosis in this registry at 40.9% — is a cancer of the lymphoid progenitor cells in the bone marrow. It is the most common cancer in children globally and is among the most curable with appropriate treatment. The dramatic improvement in ALL outcomes since the 1960s represents one of oncology's greatest achievements.
- ALL cure rates in high-income countries: 85–95% with modern risk-stratified protocols.
- Treatment consists of three phases: Induction (remission achievement, 4–6 weeks), Consolidation (preventing relapse, several months), and Maintenance (long-term low-intensity chemotherapy, 2–3 years).
- The Indian Childhood Collaborative Leukaemia (ICiCLe) group, formed in 2012 by six centres including AIIMS, established India's first MRD (minimal residual disease)-based risk-stratified ALL protocol, improving outcomes significantly.
- ICiCLe protocol outcomes: 4-year overall survival of 88% in standard-risk patients, 80% in intermediate-risk, 73% in high-risk.
- Measurable Residual Disease (MRD) testing — which detects even minute quantities of cancer cells remaining after initial treatment — is the standard of care in developed countries and is now being implemented in leading Indian centres.
- Treatment abandonment is a major challenge in resource-limited settings: studies show 20–30% of families in lower-income brackets discontinue treatment before completion, primarily due to financial burden and distance from centres.
Connection to this news: The C2S registry's finding that 94.7% of enrolled children received chemotherapy confirms the primacy of chemotherapy in childhood cancer treatment in India, consistent with the ICiCLe protocol. The 94.5% overall survival figure is notably higher than historical averages, likely reflecting the quality of care at the 20 participating tertiary centres.
National Cancer Grid and Oncology Infrastructure in India
The National Cancer Grid (NCG), established by the Tata Memorial Centre (TMC) in 2012 with government support, is India's primary network for standardising cancer care across the country. It now connects over 250 cancer centres across India, facilitating protocol harmonisation, tumour board consultations, data sharing, and joint research.
- NCG was formally supported under the National Cancer Control Programme and later the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS).
- The NCG Paediatric Oncology Working Group has been instrumental in developing standard protocols for childhood cancers across resource-limited settings.
- Tata Memorial Hospital (Mumbai) is India's apex cancer centre and the nodal institution for the NCG.
- India's cancer care infrastructure: approximately 450 operational cancer centres, but geographic and financial access remains highly unequal — rural areas face severe shortages.
- National Cancer Registry Programme (NCRP), maintained by ICMR, provides incidence and mortality data through Population-Based Cancer Registries (PBCRs) and Hospital-Based Cancer Registries (HBCRs); the C2S study complements this by tracking survivorship outcomes.
Connection to this news: The C2S registry was conducted across 20 centres, most of which are likely NCG members. The study's publication signals the maturation of India's oncology research infrastructure to produce rigorous survivor data comparable to international registries — essential for evidence-based policy planning.
Late Effects of Cancer Treatment: The Survivorship Medicine Challenge
As childhood cancer survival rates improve, the long-term health consequences of treatment — "late effects" — become a major clinical and public health concern. Survivors of childhood cancer face significantly elevated risks of secondary cancers, cardiac toxicity, endocrine dysfunction, cognitive impairment, and growth abnormalities, depending on the treatments received.
- Anthracycline chemotherapy (used in leukaemia): associated with long-term cardiomyopathy (heart muscle damage); risk increases with cumulative dose.
- Cranial radiotherapy (historically used in ALL): associated with cognitive deficits, growth hormone deficiency, and increased secondary brain tumour risk — largely replaced by high-dose intrathecal chemotherapy in modern protocols.
- Secondary malignancies: childhood cancer survivors face a 5–10 times higher risk of developing a second primary cancer compared to the general population.
- The Childhood Cancer Survivor Study (CCSS) in the USA (launched 1994, > 40,000 survivors enrolled) is the world's largest survivor registry and has driven much of the knowledge about late effects.
- India lacks equivalent long-term follow-up infrastructure; the C2S study's establishment of a survivor cohort is the first step toward building this knowledge base domestically.
Connection to this news: The 94.5% survival figure is the headline finding, but the deeper significance of the C2S registry is enabling future research on late effects in Indian survivors — essential for planning survivor follow-up clinics, modifying treatment protocols to reduce late-effect risk, and developing survivorship care guidelines specific to the Indian context.
Key Facts & Data
- Study name: Indian Childhood Cancer Survivorship (C2S) study
- Journal: The Lancet Regional Health Southeast Asia
- Registry initiated: 2016 (AIIMS New Delhi + Rajiv Gandhi Cancer Institute)
- Centres: 20 across India
- Cohort size: 5,419 children (diagnosed with cancer before age 18, in remission post-treatment)
- Five-year overall survival rate: 94.5% (entire cohort); 98.2% (among 2-year+ follow-up survivors)
- Event-free survival (2-year+ survivors): 95.7%
- Most common diagnosis: Acute leukaemia — 40.9% of cases
- Treatment modalities: Chemotherapy 94.7%, Surgery 30%, Radiotherapy 26.3%
- ICiCLe group formed: 2012 (6 centres including AIIMS)
- Historical ALL survival in India (on standard protocols): ~65% (vs 85–90% in high-income countries)
- National Cancer Grid (NCG) established: 2012 by Tata Memorial Centre
- NCG member institutions: 250+ cancer centres
- Estimated new childhood cancer cases in India annually: 50,000–75,000
- India's share of global childhood cancer cases: approximately 10%
- CCSS (USA): launched 1994, > 40,000 survivors enrolled (comparison benchmark)